NCRI Press Release, 9 November 2016
Date published: Apr 03 2018
Marker for aggressive prostate cancer doubles-up as a drug target
Download the attachmentRecent Tweets
-
To celebrate the 15th anniversary of the #NCRI2019 Conference, we’ve launched the NCRI Excellence Awards to honour… https://t.co/xVYvZ4wXhi
11 hours ago -
Looking forward to our joint event with @NHSEngland next week. It's a packed programme of great speakers, workshops… https://t.co/9wvsJZBShr
13 hours ago -
RT @CTRad_CChan : Historical day for @NCRI_partners #NCRI_CTRad as @ProfAJChalmers handed over Chair role to @MontefioreD . Big thank you to…
14 hours ago
- 18 Apr 2019New Events Manager vacancy
- 18 Apr 2019New Events Marketing Manager vacancy
- 17 Apr 2019New Clinical Studies Groups Coordinator vacancy
- 16 Apr 2019Vacancies now available for our new Cross-cutting (name TBC) Clinical Studies Group Workstreams
- 15 Apr 2019New Events Coordinator vacancy
- 8 Apr 2019Vacancy available for Workstream Chair within the new Cross-cutting Executive Group
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
- 22 Feb 2019Submit your radiotherapy proposals for guidance and feedback, deadline 7 May 2019
- 20 Feb 2019Registration now open for the NCRI Lung Cancer CSG Trials Meeting: 10 May 2019
RSS Feed